Arcede Pharma is in full swing with the preparations for clinical studies with drug candidate RCD405. CEO Mia Lundblad has announced that she will leave her position for a more research-oriented role outside the company. Lundblad will continue as CEO until the beginning of February, when the company's CFO Erik Magnusson will take over as acting CEO.